Filtered By:
Condition: Bleeding
Drug: Warfarin

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 1962 results found since Jan 2013.

Direct Oral Anticoagulation versus Warfarin in Left Ventricular Thrombus: Pooled Analysis of Randomized Controlled Trials
In conclusion, pooled analysis of RCT data favors DOAC over VKA in patients with LV thrombus both in terms of efficacy and safety. This article is protected by copyright. All rights reserved.PMID:37139934 | DOI:10.1002/jcph.2267
Source: The Journal of Clinical Pharmacology - May 4, 2023 Category: Drugs & Pharmacology Authors: Anders Olof Sahl én Haowen Jiang Yee How Lau Lucky Cuenza F Aaysha Cader Mohammed Al-Omary Purich Surunchupakorn Ka Hei Ho Jonathan Sung Derek Lee Satoshi Honda Ack Tan Wei Chieh Jonathan Yap Source Type: research

Cancers, Vol. 15, Pages 2574: Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients
Conclusions: Anticoagulation with DOACs provides a higher safety profile with respect to VKAs in terms of stroke reduction and a relative bleeding reduction risk. Further studies are needed to better assess the optimal anticoagulation strategy in cancer patients with AF.
Source: Cancers - April 30, 2023 Category: Cancer & Oncology Authors: Alberto Cereda Stefano Lucreziotti Antonio Gabriele Franchina Alessandra Laricchia Valentina De Regibus Barbara Conconi Matteo Carl à Andrea Spangaro Matteo Rocchetti Luca Ponti Alessandro Minardi Elena Sala Giuseppe Massimo Sangiorgi Gabriele Tumminello Tags: Review Source Type: research

Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
Conclusions OAC switching is common in patients with AF and patients often switch back to an OAC they have previously been on. There are aspects of OAC switching that have received little study, especially in switches from DOACs.
Source: BMJ Open - April 25, 2023 Category: General Medicine Authors: Adelakun, A. R., Turgeon, R. D., De Vera, M. A., McGrail, K., Loewen, P. S. Tags: Open access, Cardiovascular medicine Source Type: research

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research

Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines
AbstractPurpose of ReviewStroke is a leading cause of death and disability worldwide. The annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the United States, of which 87% are ischemic in nature. In addition to the management of modifiable high-risk factors to reduce the risk of recurrent stroke, antithrombotic agents (antiplatelets and anticoagulants) play an important role in secondary stroke prevention. This review will discuss the published literature on the use of antiplatelets and anticoagulants in secondary prevention of acute ischemic stroke and transient ischemic attack (TIA), ...
Source: Current Neurology and Neuroscience Reports - April 11, 2023 Category: Neuroscience Source Type: research

Dabigatran Dosing Proposal for Adults with Atrial Fibrillation: Stress-testing Renal Function Range in Real World Patients
Clin Pharmacol Ther. 2023 Apr 7. doi: 10.1002/cpt.2902. Online ahead of print.ABSTRACTDabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed 2-dose scheme compared to warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding. The pivotal phase 3 trial found dabigatran, depending on dose, is superior to warfarin in stroke reduction and similar in bleeding risk while also showing dabigatran efficacy and safety correlate with steady-state plasma concentrations. Since t...
Source: Clinical Pharmacology and Therapeutics - April 7, 2023 Category: Drugs & Pharmacology Authors: J Robert Powell Farah Al Qaraghuli Jill Fiedler-Kelly Daniel Gonzalez Daniel Weiner Source Type: research